{"product_id":"peptide-therapy-owner-makes","title":"How Much Does a Peptide Therapy Clinic Owner Make? $500k EBITDA","description":"\u003cbr\u003e\u003cdiv class=\"card_smpl\"\u003e\n\n\u003cdiv class=\"double_border\"\u003e\n\n\u003cdiv class=\"card_smpl_header\"\u003e\n\n\u003cimg src=\"\/cdn\/shop\/files\/fml_20_fml-Orange-blog-plus-icon.svg\" alt=\"Key Takeaways\" class=\"icon_how_to_use\"\u003e\n\n\u003ch3\u003eKey Takeaways\u003c\/h3\u003e\n\n\u003c\/div\u003e\n\n\u003cul class=\"lst_crct_blog\"\u003e\n\n\u003cli\u003ePatient volume must cover fixed overhead and payroll.\u003c\/li\u003e\n\n\u003cli\u003ePricing per visit drives revenue before cost cuts.\u003c\/li\u003e\n\n\u003cli\u003eMargin hinges on peptide, lab, and supply costs.\u003c\/li\u003e\n\n\u003cli\u003eRetention and efficient acquisition protect cash flow.\u003c\/li\u003e\n\n\u003c\/ul\u003e\n\n\u003c\/div\u003e\n\n\u003c\/div\u003e\u003cbr\u003e\u003cbr\u003e\u003csection class=\"fml-owner-metric-cards\" aria-label=\"Top owner income KPIs\"\u003e\u003cdiv class=\"metric-grid\"\u003e\n\u003carticle class=\"metric-card is-green\"\u003e\u003cspan class=\"metric-icon-tip\" tabindex=\"0\" data-tooltip=\"Year 1 to Year 5 pre-tax EBITDA before reserves; excludes taxes, debt service, distributions, and any reserve policy.\"\u003e\u003cimg class=\"metric-icon\" src=\"\/cdn\/shop\/files\/fml-owner-income-kpi-owner-income.svg\" alt=\"Owner income icon\" loading=\"lazy\"\u003e\u003c\/span\u003e\u003cspan\u003eOwner income\u003c\/span\u003e\u003cstrong class=\"metric-value\" tabindex=\"0\" data-tooltip=\"Year 1 to Year 5 pre-tax EBITDA before reserves; excludes taxes, debt service, distributions, and any reserve policy.\"\u003e$500k-$7.7M EBITDA\u003c\/strong\u003e\u003c\/article\u003e\u003carticle class=\"metric-card\"\u003e\u003cspan class=\"metric-icon-tip\" tabindex=\"0\" data-tooltip=\"Year 1 gross margin from revenue after peptide sourcing and lab fees; excludes payroll, rent, taxes, debt service, and reserves.\"\u003e\u003cimg class=\"metric-icon\" src=\"\/cdn\/shop\/files\/fml-owner-income-kpi-net-margin.svg\" alt=\"Gross margin icon\" loading=\"lazy\"\u003e\u003c\/span\u003e\u003cspan\u003eGross margin\u003c\/span\u003e\u003cstrong class=\"metric-value\" tabindex=\"0\" data-tooltip=\"Year 1 gross margin from revenue after peptide sourcing and lab fees; excludes payroll, rent, taxes, debt service, and reserves.\"\u003e87%\u003c\/strong\u003e\u003c\/article\u003e\u003carticle class=\"metric-card\"\u003e\u003cspan class=\"metric-icon-tip\" tabindex=\"0\" data-tooltip=\"Month 1 break-even revenue of about $85k, based on model costs and a $300 blended treatment value; excludes taxes, debt service, and reserves.\"\u003e\u003cimg class=\"metric-icon\" src=\"\/cdn\/shop\/files\/fml-owner-income-kpi-revenue-target.svg\" alt=\"Revenue for target pay icon\" loading=\"lazy\"\u003e\u003c\/span\u003e\u003cspan\u003eRevenue for target pay\u003c\/span\u003e\u003cstrong class=\"metric-value\" tabindex=\"0\" data-tooltip=\"Month 1 break-even revenue of about $85k, based on model costs and a $300 blended treatment value; excludes taxes, debt service, and reserves.\"\u003e$85k\u003c\/strong\u003e\u003c\/article\u003e\u003carticle class=\"metric-card\"\u003e\u003cspan class=\"metric-icon-tip\" tabindex=\"0\" data-tooltip=\"Hard reflects high staffing, heavy fixed costs, and a $746k cash low in Month 6; taxes, debt service, and reserves are excluded.\"\u003e\u003cimg class=\"metric-icon\" src=\"\/cdn\/shop\/files\/fml-owner-income-kpi-business-difficulty.svg\" alt=\"Business difficulty icon\" loading=\"lazy\"\u003e\u003c\/span\u003e\u003cspan\u003eBusiness difficulty\u003c\/span\u003e\u003cstrong class=\"metric-value\" tabindex=\"0\" data-tooltip=\"Hard reflects high staffing, heavy fixed costs, and a $746k cash low in Month 6; taxes, debt service, and reserves are excluded.\"\u003eHard\u003c\/strong\u003e\u003c\/article\u003e\n\u003c\/div\u003e\u003c\/section\u003e\u003cbr\u003e\u003ch2\u003e\u003cspan style=\"color: #126CFF;\"\u003eWant to estimate your clinic take-home?\n\u003c\/span\u003e\u003c\/h2\u003e\n\u003csection class=\"fml-owner-calculator\" aria-label=\"Peptide Therapy Clinic Owner Income Calculator\" data-locale=\"en-US\" data-currency=\"USD\" data-default-scenario=\"base\" data-export-filename=\"Peptide Therapy Clinic Owner Income Calculator.xlsx\" data-source-site-name=\"Financial Models Lab\" data-source-site-url=\"https:\/\/financialmodelslab.com\" data-source-page-title=\"Peptide Therapy Clinic Owner Income Calculator\" data-note-title=\"Planning note:\" data-note-text=\"Research-based planning estimate only. It is not guaranteed salary, tax advice, or owner distribution advice. Actual owner income depends on revenue, margin, payroll, reserves, and debt.\"\u003e\u003cdiv class=\"fml-owner-card\"\u003e\n\u003cheader class=\"fml-owner-header\"\u003e\u003cdiv class=\"fml-owner-heading\"\u003e\n\u003cp class=\"fml-owner-eyebrow\"\u003eOwner income calculator\u003c\/p\u003e\n\u003cp class=\"fml-owner-intro\"\u003eEstimate owner take-home and the target-pay gap from monthly revenue, gross margin, payroll, overhead, reserves, and target pay.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"fml-owner-scenarios\" aria-label=\"Income scenario presets\"\u003e\n\u003cbutton class=\"fml-owner-scenario\" type=\"button\" data-scenario=\"low\"\u003eLow\u003c\/button\u003e\u003cbutton class=\"fml-owner-scenario is-active\" type=\"button\" data-scenario=\"base\"\u003eBase\u003c\/button\u003e\u003cbutton class=\"fml-owner-scenario\" type=\"button\" data-scenario=\"high\"\u003eHigh\u003c\/button\u003e\n\u003c\/div\u003e\u003c\/header\u003e\u003cdiv class=\"fml-owner-layout\"\u003e\n\u003cform class=\"fml-owner-inputs\"\u003e\n\u003cdiv class=\"fml-owner-row\"\u003e\n\u003clabel class=\"fml-owner-label\"\u003e\u003cspan\u003eMonthly revenue\u003c\/span\u003e\u003cspan class=\"fml-owner-tooltip\" tabindex=\"0\" aria-label=\"Monthly sales collected before expenses. Low uses Year 1 run rate, base uses Year 3, and high uses Year 5.\"\u003ei\u003cspan role=\"tooltip\"\u003eMonthly sales collected before expenses. Low uses Year 1 run rate, base uses Year 3, and high uses Year 5.\u003c\/span\u003e\u003c\/span\u003e\u003c\/label\u003e\u003cdiv class=\"fml-owner-money\"\u003e\n\u003cspan\u003e$\u003c\/span\u003e\u003cinput data-owner-field=\"monthlyRevenue\" data-owner-kind=\"money\" data-owner-label=\"Monthly revenue\" data-owner-note=\"Monthly sales collected before expenses. Low uses Year 1 run rate, base uses Year 3, and high uses Year 5.\" data-low=\"122417\" data-base=\"385083\" data-high=\"772667\" name=\"monthlyRevenue\" type=\"text\" inputmode=\"numeric\" value=\"385,083\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"fml-owner-row\"\u003e\n\u003clabel class=\"fml-owner-label\"\u003e\u003cspan\u003eGross margin\u003c\/span\u003e\u003cspan class=\"fml-owner-tooltip\" tabindex=\"0\" aria-label=\"Percent left after peptide and lab direct costs. Year 1 is about 87%, and Year 5 moves closer to 89%.\"\u003ei\u003cspan role=\"tooltip\"\u003ePercent left after peptide and lab direct costs. Year 1 is about 87%, and Year 5 moves closer to 89%.\u003c\/span\u003e\u003c\/span\u003e\u003c\/label\u003e\u003cdiv class=\"fml-owner-percent\"\u003e\n\u003cinput data-owner-field=\"grossMargin\" data-owner-kind=\"percent\" data-owner-label=\"Gross margin\" data-owner-note=\"Percent left after peptide and lab direct costs. Year 1 is about 87%, and Year 5 moves closer to 89%.\" name=\"grossMargin\" type=\"range\" min=\"0\" max=\"100\" step=\"1\" data-low=\"87\" data-base=\"88\" data-high=\"89\" value=\"88\"\u003e\u003coutput\u003e88%\u003c\/output\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"fml-owner-row\"\u003e\n\u003clabel class=\"fml-owner-label\"\u003e\u003cspan\u003eLabor cost\u003c\/span\u003e\u003cspan class=\"fml-owner-tooltip\" tabindex=\"0\" aria-label=\"Monthly payroll before owner pay. This uses the clinic staffing run rate from the model.\"\u003ei\u003cspan role=\"tooltip\"\u003eMonthly payroll before owner pay. This uses the clinic staffing run rate from the model.\u003c\/span\u003e\u003c\/span\u003e\u003c\/label\u003e\u003cdiv class=\"fml-owner-money\"\u003e\n\u003cspan\u003e$\u003c\/span\u003e\u003cinput data-owner-field=\"laborCost\" data-owner-kind=\"money\" data-owner-label=\"Labor cost\" data-owner-note=\"Monthly payroll before owner pay. This uses the clinic staffing run rate from the model.\" data-low=\"47083\" data-base=\"48958\" data-high=\"50833\" name=\"laborCost\" type=\"text\" inputmode=\"numeric\" value=\"48,958\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"fml-owner-row\"\u003e\n\u003clabel class=\"fml-owner-label\"\u003e\u003cspan\u003eFixed overhead\u003c\/span\u003e\u003cspan class=\"fml-owner-tooltip\" tabindex=\"0\" aria-label=\"Lease, insurance, software, utilities, admin, and membership costs that recur each month.\"\u003ei\u003cspan role=\"tooltip\"\u003eLease, insurance, software, utilities, admin, and membership costs that recur each month.\u003c\/span\u003e\u003c\/span\u003e\u003c\/label\u003e\u003cdiv class=\"fml-owner-money\"\u003e\n\u003cspan\u003e$\u003c\/span\u003e\u003cinput data-owner-field=\"fixedOverhead\" data-owner-kind=\"money\" data-owner-label=\"Fixed overhead\" data-owner-note=\"Lease, insurance, software, utilities, admin, and membership costs that recur each month.\" data-low=\"20000\" data-base=\"20000\" data-high=\"20000\" name=\"fixedOverhead\" type=\"text\" inputmode=\"numeric\" value=\"20,000\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"fml-owner-row\"\u003e\n\u003clabel class=\"fml-owner-label\"\u003e\u003cspan\u003eMarketing\u003c\/span\u003e\u003cspan class=\"fml-owner-tooltip\" tabindex=\"0\" aria-label=\"Monthly demand spend. Low, base, and high follow the model’s Year 1, Year 3, and Year 5 marketing run rates.\"\u003ei\u003cspan role=\"tooltip\"\u003eMonthly demand spend. Low, base, and high follow the model’s Year 1, Year 3, and Year 5 marketing run rates.\u003c\/span\u003e\u003c\/span\u003e\u003c\/label\u003e\u003cdiv class=\"fml-owner-money\"\u003e\n\u003cspan\u003e$\u003c\/span\u003e\u003cinput data-owner-field=\"marketing\" data-owner-kind=\"money\" data-owner-label=\"Marketing\" data-owner-note=\"Monthly demand spend. Low, base, and high follow the model’s Year 1, Year 3, and Year 5 marketing run rates.\" data-low=\"7345\" data-base=\"19254\" data-high=\"30907\" name=\"marketing\" type=\"text\" inputmode=\"numeric\" value=\"19,254\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"fml-owner-row\"\u003e\n\u003clabel class=\"fml-owner-label\"\u003e\u003cspan\u003eDebt service\u003c\/span\u003e\u003cspan class=\"fml-owner-tooltip\" tabindex=\"0\" aria-label=\"Monthly loan or financing payment. Set this to 0 if you are not using debt.\"\u003ei\u003cspan role=\"tooltip\"\u003eMonthly loan or financing payment. Set this to 0 if you are not using debt.\u003c\/span\u003e\u003c\/span\u003e\u003c\/label\u003e\u003cdiv class=\"fml-owner-money\"\u003e\n\u003cspan\u003e$\u003c\/span\u003e\u003cinput data-owner-field=\"debtService\" data-owner-kind=\"money\" data-owner-label=\"Debt service\" data-owner-note=\"Monthly loan or financing payment. Set this to 0 if you are not using debt.\" data-low=\"0\" data-base=\"0\" data-high=\"0\" name=\"debtService\" type=\"text\" inputmode=\"numeric\" value=\"\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"fml-owner-row\"\u003e\n\u003clabel class=\"fml-owner-label\"\u003e\u003cspan\u003eTax reserve\u003c\/span\u003e\u003cspan class=\"fml-owner-tooltip\" tabindex=\"0\" aria-label=\"Percent of profit set aside before owner pay.\"\u003ei\u003cspan role=\"tooltip\"\u003ePercent of profit set aside before owner pay.\u003c\/span\u003e\u003c\/span\u003e\u003c\/label\u003e\u003cdiv class=\"fml-owner-percent\"\u003e\n\u003cinput data-owner-field=\"taxReserve\" data-owner-kind=\"percent\" data-owner-label=\"Tax reserve\" data-owner-note=\"Percent of profit set aside before owner pay.\" name=\"taxReserve\" type=\"range\" min=\"0\" max=\"45\" step=\"1\" data-low=\"15\" data-base=\"20\" data-high=\"25\" value=\"20\"\u003e\u003coutput\u003e20%\u003c\/output\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"fml-owner-row\"\u003e\n\u003clabel class=\"fml-owner-label\"\u003e\u003cspan\u003eReinvestment reserve\u003c\/span\u003e\u003cspan class=\"fml-owner-tooltip\" tabindex=\"0\" aria-label=\"Percent of profit kept in the business for growth, repairs, and cash buffer.\"\u003ei\u003cspan role=\"tooltip\"\u003ePercent of profit kept in the business for growth, repairs, and cash buffer.\u003c\/span\u003e\u003c\/span\u003e\u003c\/label\u003e\u003cdiv class=\"fml-owner-percent\"\u003e\n\u003cinput data-owner-field=\"reinvestmentReserve\" data-owner-kind=\"percent\" data-owner-label=\"Reinvestment reserve\" data-owner-note=\"Percent of profit kept in the business for growth, repairs, and cash buffer.\" name=\"reinvestmentReserve\" type=\"range\" min=\"0\" max=\"35\" step=\"1\" data-low=\"5\" data-base=\"8\" data-high=\"10\" value=\"8\"\u003e\u003coutput\u003e8%\u003c\/output\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"fml-owner-row\"\u003e\n\u003clabel class=\"fml-owner-label\"\u003e\u003cspan\u003eTarget owner pay\u003c\/span\u003e\u003cspan class=\"fml-owner-tooltip\" tabindex=\"0\" aria-label=\"Monthly owner income goal used to calculate the target-pay gap.\"\u003ei\u003cspan role=\"tooltip\"\u003eMonthly owner income goal used to calculate the target-pay gap.\u003c\/span\u003e\u003c\/span\u003e\u003c\/label\u003e\u003cdiv class=\"fml-owner-money\"\u003e\n\u003cspan\u003e$\u003c\/span\u003e\u003cinput data-owner-field=\"targetOwnerPay\" data-owner-kind=\"money\" data-owner-label=\"Target owner pay\" data-owner-note=\"Monthly owner income goal used to calculate the target-pay gap.\" data-low=\"8000\" data-base=\"15000\" data-high=\"25000\" name=\"targetOwnerPay\" type=\"text\" inputmode=\"numeric\" value=\"15,000\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/form\u003e\n\u003caside class=\"fml-owner-results\" aria-live=\"polite\"\u003e\u003cspan class=\"fml-owner-tag\"\u003eOwner income output\u003c\/span\u003e\u003cdiv class=\"fml-owner-metrics\"\u003e\n\u003cdiv class=\"fml-owner-metric is-primary\"\u003e\n\u003cspan class=\"fml-owner-metric-label\"\u003eOwner Income\u003cspan class=\"fml-owner-tooltip\" tabindex=\"0\" aria-label=\"Monthly take-home after tax and reinvestment reserves.\"\u003ei\u003cspan role=\"tooltip\"\u003eMonthly take-home after tax and reinvestment reserves.\u003c\/span\u003e\u003c\/span\u003e\u003c\/span\u003e\u003cstrong data-owner-output=\"monthlyOwnerIncome\"\u003e$180K\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"fml-owner-metric\"\u003e\n\u003cspan class=\"fml-owner-metric-label\"\u003eNet Margin\u003cspan class=\"fml-owner-tooltip\" tabindex=\"0\" aria-label=\"Owner income divided by monthly revenue.\"\u003ei\u003cspan role=\"tooltip\"\u003eOwner income divided by monthly revenue.\u003c\/span\u003e\u003c\/span\u003e\u003c\/span\u003e\u003cstrong data-owner-output=\"netProfitMargin\"\u003e47%\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"fml-owner-metric\"\u003e\n\u003cspan class=\"fml-owner-metric-label\"\u003eRevenue for Target Pay\u003cspan class=\"fml-owner-tooltip\" tabindex=\"0\" aria-label=\"Monthly revenue needed to support the target owner pay.\"\u003ei\u003cspan role=\"tooltip\"\u003eMonthly revenue needed to support the target owner pay.\u003c\/span\u003e\u003c\/span\u003e\u003c\/span\u003e\u003cstrong data-owner-output=\"revenueNeeded\"\u003e$124K\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"fml-owner-metric is-target-gap is-positive\"\u003e\n\u003cspan class=\"fml-owner-metric-label\"\u003eTarget Pay Gap\u003cspan class=\"fml-owner-tooltip\" tabindex=\"0\" aria-label=\"Owner income minus target owner pay. Negative means the target pay is not covered.\"\u003ei\u003cspan role=\"tooltip\"\u003eOwner income minus target owner pay. Negative means the target pay is not covered.\u003c\/span\u003e\u003c\/span\u003e\u003c\/span\u003e\u003cstrong data-owner-output=\"targetPayGap\"\u003e$165K\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdl class=\"fml-owner-result-list\"\u003e\n\u003cdiv\u003e\n\u003cdt\u003eAnnual owner income\u003c\/dt\u003e\n\u003cdd data-owner-output=\"annualOwnerIncome\"\u003e$2,165,712\u003c\/dd\u003e\n\u003c\/div\u003e\n\u003cdiv\u003e\n\u003cdt\u003eProfit before reserves\u003c\/dt\u003e\n\u003cdd data-owner-output=\"profitBeforeReserves\"\u003e$250,661\u003c\/dd\u003e\n\u003c\/div\u003e\n\u003cdiv\u003e\n\u003cdt\u003eTax + reinvestment reserve\u003c\/dt\u003e\n\u003cdd data-owner-output=\"reserveAmount\"\u003e$70,185\u003c\/dd\u003e\n\u003c\/div\u003e\n\u003cdiv\u003e\n\u003cdt\u003eTarget pay gap\u003c\/dt\u003e\n\u003cdd data-owner-output=\"cashAfterTargetPay\"\u003e$165,476\u003c\/dd\u003e\n\u003c\/div\u003e\n\u003c\/dl\u003e\n\u003cdiv class=\"fml-owner-bridge\"\u003e\n\u003cdiv class=\"fml-owner-bar-row\" data-owner-bridge=\"revenue\"\u003e\n\u003cspan\u003eRevenue\u003c\/span\u003e\u003cdiv\u003e\u003ci style=\"--fml-owner-share: 100%;\"\u003e\u003c\/i\u003e\u003c\/div\u003e\n\u003cb data-owner-bridge-value\u003e$385K\u003c\/b\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"fml-owner-bar-row\" data-owner-bridge=\"grossProfit\"\u003e\n\u003cspan\u003eGross profit\u003c\/span\u003e\u003cdiv\u003e\u003ci style=\"--fml-owner-share: 88%;\"\u003e\u003c\/i\u003e\u003c\/div\u003e\n\u003cb data-owner-bridge-value\u003e$339K\u003c\/b\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"fml-owner-bar-row\" data-owner-bridge=\"operatingCosts\"\u003e\n\u003cspan\u003eOperating costs\u003c\/span\u003e\u003cdiv\u003e\u003ci style=\"--fml-owner-share: 23%;\"\u003e\u003c\/i\u003e\u003c\/div\u003e\n\u003cb data-owner-bridge-value\u003e$88,212\u003c\/b\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"fml-owner-bar-row\" data-owner-bridge=\"reserveAmount\"\u003e\n\u003cspan\u003eReserves\u003c\/span\u003e\u003cdiv\u003e\u003ci style=\"--fml-owner-share: 18%;\"\u003e\u003c\/i\u003e\u003c\/div\u003e\n\u003cb data-owner-bridge-value\u003e$70,185\u003c\/b\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"fml-owner-bar-row\" data-owner-bridge=\"ownerIncome\"\u003e\n\u003cspan\u003eOwner income\u003c\/span\u003e\u003cdiv\u003e\u003ci style=\"--fml-owner-share: 47%;\"\u003e\u003c\/i\u003e\u003c\/div\u003e\n\u003cb data-owner-bridge-value\u003e$180K\u003c\/b\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"fml-owner-export\" type=\"button\" data-owner-export\u003eEXPORT XLSX\u003c\/button\u003e\u003c\/aside\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"fml-owner-note\"\u003e\n\u003cspan class=\"fml-owner-note-icon\" aria-hidden=\"true\"\u003e!\u003c\/span\u003e\u003cp\u003e\u003cstrong\u003ePlanning note:\u003c\/strong\u003e Research-based planning estimate only. It is not guaranteed salary, tax advice, or owner distribution advice. Actual owner income depends on revenue, margin, payroll, reserves, and debt.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003c\/section\u003e\u003cbr\u003e\u003cdiv class=\"container_new_design_blog\"\u003e\n\n\u003cdiv class=\"text-section_blog text-2_new_design_blog\"\u003e\n\n\u003cdiv class=\"line_top_blog\"\u003e\u003cbr\u003e\u003c\/div\u003e\n\n\u003ch3\u003e\u003cspan style=\"color: #126CFF;\"\u003eWant to pressure-test the Peptide Therapy Clinic model?\u003c\/span\u003e\u003c\/h3\u003e\n\n\u003cp\u003eThis dashboard should show \u003cstrong\u003erevenue\u003c\/strong\u003e, \u003cstrong\u003eEBITDA\u003c\/strong\u003e, owner income, breakeven, payback, and cash need; open the \u003ca href=\"\/products\/peptide-therapy-financial-model\"\u003ePeptide Therapy Clinic Financial Model Template\u003c\/a\u003e to test provider count, monthly treatments, capacity, price, COGS, payroll, overhead, and capex. Use Year 1, Year 3, and Year 5 scenarios.\u003c\/p\u003e\n\n\u003ch4\u003eKey model checks\u003c\/h4\u003e\n\u003cul class=\"lst_crct_blog\"\u003e\n\u003cli\u003eOwner income output\u003c\/li\u003e\n\u003cli\u003eCapacity-driven revenue build\u003c\/li\u003e\n\u003cli\u003eScenario charts and tables\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003c\/div\u003e\n\n\u003cdiv class=\"image-section_blog image-2_new_design_blog\"\u003e\n\n\u003cdiv class=\"preview-card\" data-preview-src=\"\/cdn\/shop\/files\/peptide-therapy-financial-model-dashboard-financialmodelslab_debfa97f-6430-4871-8f55-49edc563edcf.webp\"\u003e\n\u003cimg class=\"preview-img\" width=\"100%\" height=\"auto\" src=\"\/cdn\/shop\/files\/peptide-therapy-financial-model-dashboard-financialmodelslab_debfa97f-6430-4871-8f55-49edc563edcf.webp?width=500\" alt=\"Peptide Therapy Clinic financial model dashboard summarizes key KPIs, runway\/cash and performance with a dynamic dashboard, investor-ready charts and quick visibility into cash-flow blind spots.\"\u003e\n\u003cdiv class=\"preview-overlay\"\u003e\n\u003cbutton class=\"preview-btn\" type=\"button\" style=\"align-items: center; vertical-align: middle; display: inline-flex; justify-content: center; gap: 6px; line-height: 1;\"\u003e\nPREVIEW \u003csvg fill=\"#fff\" xmlns=\"http:\/\/www.w3.org\/2000\/svg\" aria-hidden=\"true\" focusable=\"false\" role=\"presentation\" viewbox=\"0 0 448 512\" width=\"14\"\u003e\u003cpath d=\"M416 176V86.63L246.6 256L416 425.4V336c0-8.844 7.156-16 16-16s16 7.156 16 16v128c0 8.844-7.156 16-16 16h-128c-8.844 0-16-7.156-16-16s7.156-16 16-16h89.38L224 278.6L54.63 448H144C152.8 448 160 455.2 160 464S152.8 480 144 480h-128C7.156 480 0 472.8 0 464v-128C0 327.2 7.156 320 16 320S32 327.2 32 336v89.38L201.4 256L32 86.63V176C32 184.8 24.84 192 16 192S0 184.8 0 176v-128C0 39.16 7.156 32 16 32h128C152.8 32 160 39.16 160 48S152.8 64 144 64H54.63L224 233.4L393.4 64H304C295.2 64 288 56.84 288 48S295.2 32 304 32h128C440.8 32 448 39.16 448 48v128C448 184.8 440.8 192 432 192S416 184.8 416 176z\"\u003e\u003c\/path\u003e\u003c\/svg\u003e\n\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\n\u003c\/div\u003e\n\u003c\/div\u003e\n\n\u003ch2\u003e\u003cspan style=\"color: #126CFF;\"\u003eHow much can a peptide therapy clinic owner make?\u003c\/span\u003e\u003c\/h2\u003e\u003cbr\u003e\n\u003cp\u003eA Peptide Therapy Clinic owner can make what remains after expenses and reserves, not revenue alone; the researched model shows \u003cstrong\u003e$500k Year 1 EBITDA\u003c\/strong\u003e on \u003cstrong\u003e$1.469M revenue\u003c\/strong\u003e, rising to \u003cstrong\u003e$7.668M Year 5 EBITDA\u003c\/strong\u003e on \u003cstrong\u003e$9.272M revenue\u003c\/strong\u003e. EBITDA means profit before interest, taxes, depreciation, and amortization, so safe owner draw should leave cash for taxes, debt service, inventory, compliance, staffing, and marketing; use \u003ca href=\"\/blogs\/write-business-plan\/peptide-therapy\"\u003eHow To Write A Business Plan For Peptide Therapy Clinic?\u003c\/a\u003e to map that cash plan.\u003c\/p\u003e\n\u003cdiv class=\"container_2_clmn_row\"\u003e\n\u003cdiv class=\"card_smpl blue_card\"\u003e\n\u003cdiv class=\"card_smpl_header\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/fml_20_fml-Orange-blog-colons-icon.svg\" alt=\"Icon\" class=\"icon_how_to_use\"\u003e\u003ch3\u003eIncome drivers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cul class=\"lst_crct_blog\"\u003e\n\u003cli\u003e\n\u003cstrong\u003e$500k\u003c\/strong\u003e Year 1 EBITDA\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$1.469M\u003c\/strong\u003e Year 1 revenue\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$7.668M\u003c\/strong\u003e Year 5 EBITDA\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$9.272M\u003c\/strong\u003e Year 5 revenue\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"card_smpl\"\u003e\n\u003cdiv class=\"card_smpl_header\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/fml_20_fml-Orange-blog-intro-icon.svg\" alt=\"Icon\" class=\"icon_how_to_use\"\u003e\u003ch3\u003eDraw limits\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cul class=\"lst_crct_blog\"\u003e\n\u003cli\u003eReserve for \u003cstrong\u003etaxes\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eCover \u003cstrong\u003edebt service\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eFund \u003cstrong\u003einventory and compliance\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eWatch \u003cstrong\u003epatient volume, provider use, pricing\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cbr\u003e\u003ch2\u003e\u003cspan style=\"color: #126CFF;\"\u003eHow does the owner’s role change peptide therapy clinic income?\u003c\/span\u003e\u003c\/h2\u003e\u003cbr\u003e\n\u003cp\u003e\u003cstrong\u003eOwner-operated income\u003c\/strong\u003e can look stronger in a \u003cstrong\u003ePeptide Therapy Clinic\u003c\/strong\u003e because the owner may replace paid management or clinical labor, but that also means they are buying a job with their time. A delegated provider model adds capacity, yet it also raises payroll, oversight, scheduling, and compliance work. Here’s the quick math: staffing can scale from \u003cstrong\u003e1 Medical Doctor, 1 Nurse Practitioner, and 2 Registered Nurses\u003c\/strong\u003e in Year 1 to \u003cstrong\u003e3 Medical Doctors, 5 Nurse Practitioners, and 6 Registered Nurses\u003c\/strong\u003e in Year 5, so passive ownership is not simple.\u003c\/p\u003e\n\u003cdiv class=\"container_2_clmn_row\"\u003e\n\u003cdiv class=\"card_smpl\"\u003e\n\u003cdiv class=\"card_smpl_header\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/fml_20_fml-Orange-blog-intro-icon.svg\" alt=\"Icon\" class=\"icon_how_to_use\"\u003e\u003ch3\u003eOwner-led income\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cul class=\"lst_crct_blog\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eHigher take-home\u003c\/strong\u003e if labor is self-run.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eNo paid manager\u003c\/strong\u003e lowers fixed cost.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eOwner time\u003c\/strong\u003e becomes the bottleneck.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eOne-liner:\u003c\/strong\u003e more control, less freedom.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"card_smpl blue_card\"\u003e\n\u003cdiv class=\"card_smpl_header\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/fml_20_fml-Orange-blog-colons-icon.svg\" alt=\"Icon\" class=\"icon_how_to_use\"\u003e\u003ch3\u003eDelegated model\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cul class=\"lst_crct_blog\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eMore providers\u003c\/strong\u003e increase treatment capacity.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePayroll grows\u003c\/strong\u003e with each role added.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eCompliance work\u003c\/strong\u003e still needs active oversight.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eOne-liner:\u003c\/strong\u003e scale is real, so is control.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cbr\u003e\u003ch2\u003e\u003cspan style=\"color: #126CFF;\"\u003eAre peptide therapy clinics profitable after operating costs?\u003c\/span\u003e\u003c\/h2\u003e\u003cbr\u003e\n\u003cp\u003eIf you’re asking whether a \u003cstrong\u003ePeptide Therapy Clinic\u003c\/strong\u003e can be profitable after operating costs, the answer is \u003cstrong\u003eyes\u003c\/strong\u003e under the researched assumptions. The clinic is profitable from \u003cstrong\u003eMonth 1\u003c\/strong\u003e, with \u003cstrong\u003e$500k\u003c\/strong\u003e Year 1 EBITDA and a \u003cstrong\u003e340%\u003c\/strong\u003e EBITDA margin; see \u003ca href=\"\/blogs\/how-to-open\/peptide-therapy\"\u003eHow To Launch Peptide Therapy Clinic Business?\u003c\/a\u003e for the setup path. Direct peptide and lab costs are \u003cstrong\u003e130%\u003c\/strong\u003e of revenue in Year 1 and fall to \u003cstrong\u003e112%\u003c\/strong\u003e by Year 5, so the margin depends on volume and cost control.\u003c\/p\u003e\n\u003cdiv class=\"container_2_clmn_row\"\u003e\n\u003cdiv class=\"card_smpl blue_card\"\u003e\n\u003cdiv class=\"card_smpl_header\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/fml_20_fml-Orange-blog-colons-icon.svg\" alt=\"Icon\" class=\"icon_how_to_use\"\u003e\u003ch3\u003eWhy it works\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cul class=\"lst_crct_blog\"\u003e\n\u003cli\u003e\n\u003cstrong\u003e$500k\u003c\/strong\u003e Year 1 EBITDA\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e340%\u003c\/strong\u003e EBITDA margin\u003c\/li\u003e\n\u003cli\u003eProfitable from \u003cstrong\u003eMonth 1\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eCosts improve to \u003cstrong\u003e112%\u003c\/strong\u003e by Year 5\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"card_smpl\"\u003e\n\u003cdiv class=\"card_smpl_header\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/fml_20_fml-Orange-blog-intro-icon.svg\" alt=\"Icon\" class=\"icon_how_to_use\"\u003e\u003ch3\u003eWhat can break it\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cul class=\"lst_crct_blog\"\u003e\n\u003cli\u003e\n\u003cstrong\u003e$125k\u003c\/strong\u003e monthly lease\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$32k\u003c\/strong\u003e malpractice and liability insurance\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$11k\u003c\/strong\u003e EMR and HIPAA software\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$18k\u003c\/strong\u003e utilities and maintenance\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003cbr\u003e\u003cbr\u003e\u003cbr\u003e\n\n\u003ch2\u003e\u003cspan style=\"color: #126CFF;\"\u003eWant to see what drives owner income?\n\u003c\/span\u003e\u003c\/h2\u003e\n\u003csection class=\"fml-main-income-drivers\" aria-label=\"Six income drivers for the peptide therapy clinic.\"\u003e\u003carticle class=\"driver-option is-cards\"\u003e\u003cdiv class=\"main-driver-grid\"\u003e\n\u003carticle class=\"main-driver-card is-primary\"\u003e\u003cdiv class=\"main-driver-heading\"\u003e\n\u003cspan class=\"driver-rank\"\u003e1\u003c\/span\u003e\u003ch4\u003ePatient Volume\u003c\/h4\u003e\n\u003c\/div\u003e\n\u003cstrong\u003e122K-773K\/mo\u003c\/strong\u003e\u003cp\u003eMore visits lift revenue from about $122K a month in Year 1 to about $773K a month in Year 5, and that scale drives most owner cash.\u003c\/p\u003e\u003c\/article\u003e\u003carticle class=\"main-driver-card\"\u003e\u003cdiv class=\"main-driver-heading\"\u003e\n\u003cspan class=\"driver-rank\"\u003e2\u003c\/span\u003e\u003ch4\u003eTreatment Pricing\u003c\/h4\u003e\n\u003c\/div\u003e\n\u003cstrong\u003e125-950\u003c\/strong\u003e\u003cp\u003ePrices run from $125 to $950, so even small raises spread across the whole schedule and add straight to take-home.\u003c\/p\u003e\u003c\/article\u003e\u003carticle class=\"main-driver-card\"\u003e\u003cdiv class=\"main-driver-heading\"\u003e\n\u003cspan class=\"driver-rank\"\u003e3\u003c\/span\u003e\u003ch4\u003eGross Margin\u003c\/h4\u003e\n\u003c\/div\u003e\n\u003cstrong\u003e87%\u003c\/strong\u003e\u003cp\u003ePeptide sourcing and lab fees take 13% of revenue, so about 87% stays to pay overhead and profit.\u003c\/p\u003e\u003c\/article\u003e\u003carticle class=\"main-driver-card\"\u003e\u003cdiv class=\"main-driver-heading\"\u003e\n\u003cspan class=\"driver-rank\"\u003e4\u003c\/span\u003e\u003ch4\u003eProvider Model\u003c\/h4\u003e\n\u003c\/div\u003e\n\u003cstrong\u003e6-19 FTE\u003c\/strong\u003e\u003cp\u003eThe care team scales from 6 to 19 FTE, so more treatments can be sold without one clinician capping revenue.\u003c\/p\u003e\u003c\/article\u003e\u003carticle class=\"main-driver-card\"\u003e\u003cdiv class=\"main-driver-heading\"\u003e\n\u003cspan class=\"driver-rank\"\u003e5\u003c\/span\u003e\u003ch4\u003eRetention\u003c\/h4\u003e\n\u003c\/div\u003e\n\u003cstrong\u003e660\/mo\u003c\/strong\u003e\u003cp\u003eKeeping follow-up patients on schedule protects the 660 monthly treatment slots already built into the plan.\u003c\/p\u003e\u003c\/article\u003e\u003carticle class=\"main-driver-card\"\u003e\u003cdiv class=\"main-driver-heading\"\u003e\n\u003cspan class=\"driver-rank\"\u003e6\u003c\/span\u003e\u003ch4\u003eAcquisition Efficiency\u003c\/h4\u003e\n\u003c\/div\u003e\n\u003cstrong\u003e6.0-4.0\u003c\/strong\u003e\u003cp\u003eDigital marketing cost falls from 6.0 to 4.0, so less paid growth spend drops into profit after Month 1 breakeven.\u003c\/p\u003e\u003c\/article\u003e\n\u003c\/div\u003e\u003c\/article\u003e\u003c\/section\u003e\u003cbr\u003e\u003ch2\u003e\u003cspan style=\"color: #126CFF;\"\u003ePeptide Therapy Clinic Core Six Income Drivers\u003c\/span\u003e\u003c\/h2\u003e\u003cbr\u003e\u003cbr\u003e\n\u003ch3\u003e\u003cspan style=\"color: #126CFF;\"\u003ePatient Demand And Active Patient Count\u003c\/span\u003e\u003c\/h3\u003e\u003cbr\u003e\n\u003cdiv class=\"container_new_design_timeline\"\u003e\n  \u003cdiv class=\"left-row1\"\u003e\n    \u003ch3\u003eActive Patient Count\u003c\/h3\u003e\n    \u003cp\u003e\u003cstrong\u003eActive patient count\u003c\/strong\u003e is the real revenue engine here: consults only matter if they turn into starts, then follow-ups, and then enough repeat visits to keep providers busy. The model assumes \u003cstrong\u003e408 treatments per month in Year 1\u003c\/strong\u003e across provider types, so owner income rises only when those slots are filled without adding idle payroll or excess staff.\u003c\/p\u003e\n    \u003cp\u003eHere’s the quick math: more active patients spread fixed overhead and payroll across more visits, which lifts cash flow and profit. If demand is thin, adding providers too early pushes cost up before revenue catches up. One clean rule: \u003cstrong\u003evolume before hiring\u003c\/strong\u003e.\u003c\/p\u003e\n  \u003c\/div\u003e\n  \u003cdiv class=\"right-row1\"\u003e\n    \u003cdiv class=\"tips-box\"\u003e\n      \u003ch3\u003eTrack Starts, Not Just Leads\u003c\/h3\u003e\n      \u003cp\u003eMeasure \u003cstrong\u003econsult-to-start conversion\u003c\/strong\u003e, active patients per provider, and follow-up fill rate each month. Those three inputs tell you if the schedule can support more revenue or if you’re just buying empty capacity. If follow-ups do not stay full, owner pay falls even when lead flow looks healthy.\u003c\/p\u003e\n      \u003cp\u003eUse a simple control check: planned treatments versus actual treatments versus provider capacity. When starts lag, tighten scheduling, reactivation, and retention before hiring. If demand keeps pace with the modeled \u003cstrong\u003e408 monthly treatments\u003c\/strong\u003e, overhead absorption improves and take-home income has room to grow.\u003c\/p\u003e\n      \u003cul class=\"lst_crct_blog\"\u003e\n        \u003cli\u003e\n\u003cstrong\u003eConsults\u003c\/strong\u003e that become starts\u003c\/li\u003e\n        \u003cli\u003e\n\u003cstrong\u003eActive patients\u003c\/strong\u003e per provider\u003c\/li\u003e\n        \u003cli\u003e\n\u003cstrong\u003eFollow-up fill rate\u003c\/strong\u003e each month\u003c\/li\u003e\n        \u003cli\u003e\n\u003cstrong\u003eUnused capacity\u003c\/strong\u003e before hiring\u003c\/li\u003e\n      \u003c\/ul\u003e\n    \u003c\/div\u003e\n  \u003c\/div\u003e\n  \u003cdiv class=\"timeline\"\u003e\u003c\/div\u003e\n  \u003cdiv class=\"step-circle step1\"\u003e1\u003c\/div\u003e\n\u003c\/div\u003e\u003cbr\u003e\u003ch3\u003e\u003cspan style=\"color: #126CFF;\"\u003ePricing And Revenue Per Patient\u003c\/span\u003e\u003c\/h3\u003e\u003cbr\u003e\n\u003cdiv class=\"container_new_design_timeline\"\u003e\n  \u003cdiv class=\"right-row2\"\u003e\n    \u003ch3\u003ePricing Per Patient\u003c\/h3\u003e\n    \u003cp\u003ePricing sets revenue per patient before any cost cut. Year 1 service prices are \u003cstrong\u003e$850\u003c\/strong\u003e for Medical Doctor visits, \u003cstrong\u003e$450\u003c\/strong\u003e for Nurse Practitioner visits, \u003cstrong\u003e$250\u003c\/strong\u003e for Registered Nurse visits, \u003cstrong\u003e$175\u003c\/strong\u003e for Health Coach visits, and \u003cstrong\u003e$125\u003c\/strong\u003e for Phlebotomist visits. If the visit mix stays the same, price alone can lift owner income without adding more patients.\u003c\/p\u003e\n    \u003cp\u003eBy Year 5, those prices rise to \u003cstrong\u003e$950\u003c\/strong\u003e, \u003cstrong\u003e$510\u003c\/strong\u003e, \u003cstrong\u003e$290\u003c\/strong\u003e, \u003cstrong\u003e$195\u003c\/strong\u003e, and \u003cstrong\u003e$145\u003c\/strong\u003e, which is about \u003cstrong\u003e11% to 16%\u003c\/strong\u003e higher by role. Packages, memberships, consult fees, and follow-up pricing can add more revenue, but only if patient demand and provider capacity support the extra touches.\u003c\/p\u003e\n  \u003c\/div\u003e\n  \u003cdiv class=\"left-row2\"\u003e\n    \u003cdiv class=\"tips-box\"\u003e\n      \u003ch3\u003eTrack Revenue per Active Patient\u003c\/h3\u003e\n      \u003cp\u003eMeasure \u003cstrong\u003erevenue per active patient\u003c\/strong\u003e, not just visit count. Here’s the quick math: a higher-price mix raises top-line revenue first, then improves cash flow and owner draw if schedules stay full. A schedule heavy on \u003cstrong\u003eMedical Doctor\u003c\/strong\u003e visits will pay more than one built around \u003cstrong\u003eRN\u003c\/strong\u003e or \u003cstrong\u003eHealth Coach\u003c\/strong\u003e visits.\u003c\/p\u003e\n      \u003cp\u003eTrack three things: \u003cstrong\u003evisit mix\u003c\/strong\u003e, \u003cstrong\u003efollow-up rate\u003c\/strong\u003e, and \u003cstrong\u003emembership attach rate\u003c\/strong\u003e. Test package pricing only when open slots remain. If consult fees or follow-up prices rise but starts drop, total income can fall even with a better ticket.\u003c\/p\u003e\n      \u003cul class=\"lst_crct_blog\"\u003e\n        \u003cli\u003ePrice by service level.\u003c\/li\u003e\n        \u003cli\u003eWatch capacity by provider.\u003c\/li\u003e\n        \u003cli\u003eTest follow-up conversion.\u003c\/li\u003e\n        \u003cli\u003eProtect revenue per patient.\u003c\/li\u003e\n      \u003c\/ul\u003e\n    \u003c\/div\u003e\n  \u003c\/div\u003e\n  \u003cdiv class=\"timeline\"\u003e\u003c\/div\u003e\n  \u003cdiv class=\"step-circle step2\"\u003e2\u003c\/div\u003e\n\u003c\/div\u003e\u003cbr\u003e\u003cbr\u003e\u003ch3\u003e\u003cspan style=\"color: #126CFF;\"\u003eGross Margin After Peptide And Lab Costs\u003c\/span\u003e\u003c\/h3\u003e\u003cbr\u003e\n\u003cdiv class=\"container_new_design_timeline\"\u003e\n  \u003cdiv class=\"left-row3\"\u003e\n    \u003ch3\u003eGross Margin After Lab And Peptide Costs\u003c\/h3\u003e\n    \u003cp\u003eWhen peptide sourcing and lab fees stay under control, more of each treatment dollar turns into cash that can cover payroll, marketing, rent, and owner pay. The model shows \u003cstrong\u003epeptide sourcing at 85% of revenue\u003c\/strong\u003e and \u003cstrong\u003ediagnostic lab fees at 45%\u003c\/strong\u003e in Year 1, then \u003cstrong\u003e75%\u003c\/strong\u003e and \u003cstrong\u003e37%\u003c\/strong\u003e by Year 5. The stated gross margin after those direct costs is \u003cstrong\u003e870%\u003c\/strong\u003e in Year 1 and \u003cstrong\u003e888%\u003c\/strong\u003e in Year 5, so the owner’s income depends on keeping clinical quality while tightening COGS.\u003c\/p\u003e\n    \u003cp\u003eWhat this includes is simple: peptide therapy supply cost, lab testing, and related direct materials. The key inputs are treatment revenue, peptide cost as a percent of revenue, lab fee as a percent of revenue, and any added supply cost, which is listed at \u003cstrong\u003e25%\u003c\/strong\u003e in Year 1. If sourcing slips or documentation is weak, margin can look better on paper than it is in cash.\u003c\/p\u003e\n  \u003c\/div\u003e\n  \u003cdiv class=\"right-row3\"\u003e\n    \u003cdiv class=\"tips-box\"\u003e\n      \u003ch3\u003eTrack COGS And Lab Cost Per Start\u003c\/h3\u003e\n      \u003cp\u003eTrack \u003cstrong\u003epeptide cost per treatment\u003c\/strong\u003e, \u003cstrong\u003elab cost per patient\u003c\/strong\u003e, and gross margin by protocol. Here’s the quick math: if revenue rises but direct costs rise faster, the owner gets less cash for draw and overhead. Tie every protocol to a standard cost sheet so you can see where each test, vial, and supply line lands before it hits the P\u0026amp;L.\u003c\/p\u003e\n      \u003cp\u003eImprove this driver by reviewing vendor pricing, test ordering rules, and refill timing without cutting compliance. Use the same documentation standard on every chart, because weak sourcing or shortcuts can raise legal and cash risk at the same time. One clean rule helps: if a cost does not change care quality, it should be tested against margin before it becomes standard.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/div\u003e\n  \u003cdiv class=\"timeline\"\u003e\u003c\/div\u003e\n  \u003cdiv class=\"step-circle step3\"\u003e3\u003c\/div\u003e\n\u003c\/div\u003e\u003cbr\u003e\u003cbr\u003e\u003ch3\u003e\u003cspan style=\"color: #126CFF;\"\u003eProvider Staffing And Medical Oversight\u003c\/span\u003e\u003c\/h3\u003e\u003cbr\u003e\n\u003cdiv class=\"container_new_design_timeline\"\u003e\n\u003cdiv class=\"right-row4\"\u003e\n\u003ch3\u003eProvider Staffing and Medical Oversight\u003c\/h3\u003e\n\u003cp\u003eWhen staffing gets ahead of demand, owner pay gets squeezed fast. Year 1 fixed payroll is \u003cstrong\u003e$285k\u003c\/strong\u003e for the Medical Director plus \u003cstrong\u003e$95k\u003c\/strong\u003e Clinic Manager, \u003cstrong\u003e$55k\u003c\/strong\u003e Patient Coordinator, \u003cstrong\u003e$85k\u003c\/strong\u003e Marketing Manager, and \u003cstrong\u003e$45k\u003c\/strong\u003e Front Desk Receptionist, or about \u003cstrong\u003e$47.1k per month\u003c\/strong\u003e before any owner draw.\u003c\/p\u003e\n\u003cp\u003eThe clinic starts with \u003cstrong\u003e1 Medical Doctor and 1 Nurse Practitioner\u003c\/strong\u003e and scales to \u003cstrong\u003e3 Medical Doctors and 5 Nurse Practitioners\u003c\/strong\u003e by Year 5. That helps capacity, but only if supervision, scheduling, and compliance stay tight; otherwise payroll rises faster than revenue and cash flow gets thin.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"left-row4\"\u003e\n\u003cdiv class=\"tips-box\"\u003e\n\u003ch3\u003eTrack provider load, not headcount\u003c\/h3\u003e\n\u003cp\u003eMeasure visits per clinician, medical director time, and schedule fill rate, then tie hiring to booked demand. Here’s the quick math: the fixed team costs \u003cstrong\u003e$565k a year\u003c\/strong\u003e, so every added provider needs enough booked, billable work to cover their share of overhead and still leave room for owner pay.\u003c\/p\u003e\n\u003cul class=\"lst_crct_blog\"\u003e\n\u003cli\u003eTrack visits per provider weekly\u003c\/li\u003e\n\u003cli\u003eWatch no-show and reschedule rates\u003c\/li\u003e\n\u003cli\u003eSet supervision and chart review rules\u003c\/li\u003e\n\u003cli\u003eHire only against booked demand\u003c\/li\u003e\n\u003cli\u003eUse one schedule, not ad hoc coverage\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"timeline\"\u003e\u003c\/div\u003e\n\u003cdiv class=\"step-circle step4\"\u003e4\u003c\/div\u003e\n\u003c\/div\u003e\u003cbr\u003e\u003cbr\u003e\u003ch3\u003e\u003cspan style=\"color: #126CFF;\"\u003eRetention And Recurring Follow-Up Revenue\u003c\/span\u003e\u003c\/h3\u003e\u003cbr\u003e\n\u003cdiv class=\"container_new_design_timeline\"\u003e\n  \u003cdiv class=\"left-row5\"\u003e\n    \u003ch3\u003eRetention and Follow-Up Revenue\u003c\/h3\u003e\n    \u003cp\u003eIn a peptide clinic, \u003cstrong\u003eretention\u003c\/strong\u003e means patients keep coming back for refills, follow-ups, and lab reviews instead of stopping after one cycle. That keeps the schedule full with fewer new consults, so revenue is steadier and more of the cash can reach the owner. In\nthe model, revenue grows from \u003cstrong\u003e$1,469M\u003c\/strong\u003e in Year 1 to \u003cstrong\u003e$9,272M\u003c\/strong\u003e in Year 5 only when follow-up volume stays productive.\u003c\/p\u003e\n  \u003c\/div\u003e\n  \u003cdiv class=\"right-row5\"\u003e\n    \u003cdiv class=\"tips-box\"\u003e\n      \u003ch3\u003eTrack Repeats Before You Add Staff\u003c\/h3\u003e\n      \u003cp\u003eTrack \u003cstrong\u003erepeat-visit rate\u003c\/strong\u003e, booked-next-visit rate, membership renewals, and the average days between visits. If the first-treatment cohort does not return, new leads have to replace them, which raises marketing pressure and makes profit less predictable. The fastest fix is simple: schedule the next refill or lab review before the patient leaves, so the next revenue date is already on the calendar.\u003c\/p\u003e\n      \u003cul class=\"lst_crct_blog\"\u003e\n        \u003cli\u003eMeasure repeats by patient cohort.\u003c\/li\u003e\n        \u003cli\u003eWatch refill and lab gaps.\u003c\/li\u003e\n        \u003cli\u003eTrack renewals and cancellations.\u003c\/li\u003e\n        \u003cli\u003eFill open slots with existing patients first.\u003c\/li\u003e\n      \u003c\/ul\u003e\n    \u003c\/div\u003e\n  \u003c\/div\u003e\n  \u003cdiv class=\"timeline\"\u003e\u003c\/div\u003e\n  \u003cdiv class=\"step-circle step5\"\u003e5\u003c\/div\u003e\n\u003c\/div\u003e\u003cbr\u003e\u003cbr\u003e\u003ch3\u003e\u003cspan style=\"color: #126CFF;\"\u003eMarketing Efficiency And Acquisition Cost\u003c\/span\u003e\u003c\/h3\u003e\u003cbr\u003e\n\u003cdiv class=\"container_new_design_timeline\"\u003e\n  \u003cdiv class=\"right-row6\"\u003e\n    \u003ch3\u003eMarketing Efficiency\u003c\/h3\u003e\n    \u003cp\u003eFor a peptide therapy clinic, \u003cstrong\u003emarketing efficiency\u003c\/strong\u003e is the gap between spending on leads and getting paid starts. In the model, \u003cstrong\u003eYear 1 digital marketing and acquisition = 60% of revenue\u003c\/strong\u003e, then falls to \u003cstrong\u003e40% by Year 5\u003c\/strong\u003e. That only helps owner income if consults turn into treatment plans fast enough to cover contribution margin and fixed payroll. If they do not, EBITDA gets squeezed.\u003c\/p\u003e\n    \u003cp\u003eHere’s the quick math: watch \u003cstrong\u003ecost per qualified consult\u003c\/strong\u003e, \u003cstrong\u003econsult-to-start conversion\u003c\/strong\u003e, \u003cstrong\u003erevenue per active patient\u003c\/strong\u003e, and \u003cstrong\u003epayback period\u003c\/strong\u003e. One bad step in the funnel can turn growth into cash burn. The owner pays for wasted leads twice: once in marketing spend and again in idle clinical capacity.\u003c\/p\u003e\n  \u003c\/div\u003e\n  \u003cdiv class=\"left-row6\"\u003e\n    \u003cdiv class=\"tips-box\"\u003e\n      \u003ch3\u003eTighten Acquisition Payback\u003c\/h3\u003e\n      \u003cp\u003eTrack each source from lead to start, then stop buying traffic that does not produce enough margin. Keep spend tied to contribution, not lead volume. That is the cleanest way to protect take-home income.\u003c\/p\u003e\n      \u003cul class=\"lst_crct_blog\"\u003e\n        \u003cli\u003eMeasure qualified consult cost\u003c\/li\u003e\n        \u003cli\u003eTrack start rate by source\u003c\/li\u003e\n        \u003cli\u003eCompare payback by campaign\u003c\/li\u003e\n        \u003cli\u003eWatch revenue per active patient\u003c\/li\u003e\n      \u003c\/ul\u003e\n      \u003cp\u003eIf leads convert slowly or into low-margin plans, cut spend fast. If acquisition is efficient, faster payback frees cash for staffing, retention, and owner pay.\u003c\/p\u003e\n    \u003c\/div\u003e\n  \u003c\/div\u003e\n  \u003cdiv class=\"timeline\"\u003e\u003c\/div\u003e\n  \u003cdiv class=\"step-circle step6\"\u003e6\u003c\/div\u003e\n\u003c\/div\u003e\u003cbr\u003e\u003cbr\u003e\u003cbr\u003e\u003ch2\u003e\u003cspan style=\"color: #126CFF;\"\u003eCompare launch, growth, and mature owner-income scenarios\n\u003c\/span\u003e\u003c\/h2\u003e\n\u003csection class=\"fml-scenario-table\" aria-label=\"Peptide Therapy Clinic Owner Income Scenarios\" data-site-name=\"Financial Models Lab\" data-site-url=\"https:\/\/financialmodelslab.com\" data-source-title=\"Peptide Therapy Clinic Owner Income Scenarios\" data-note-label=\"Planning note\" data-note-text=\"Scenario ranges are researched planning assumptions, not guaranteed earnings, salary promises, tax advice, or distributions.\"\u003e\u003cdiv class=\"fml-scenario-table-card\"\u003e\n\u003cheader class=\"fml-scenario-table-header\"\u003e\u003cdiv\u003e\n\u003cp class=\"fml-scenario-table-eyebrow\"\u003eOwner income scenarios\u003c\/p\u003e\n\u003cp class=\"fml-scenario-table-description\"\u003eOwner income changes quickly here because staffing, compliance, marketing, and cash needs rise with volume. The three cases show how Year 1, Year 3, and Year 5 model results affect cash left for the owner.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"fml-scenario-table-actions\"\u003e\u003cbutton class=\"fml-scenario-table-export\" type=\"button\" data-scenario-export\u003eEXPORT XLSX\u003c\/button\u003e\u003c\/div\u003e\u003c\/header\u003e\u003cdiv class=\"fml-scenario-table-wrap\"\u003e\u003ctable class=\"fml-scenario-table-grid\"\u003e\n\u003ccaption\u003eCompare low, base, and high owner income cases by model year.\u003c\/caption\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth class=\"fml-scenario-table-stub\" scope=\"col\" data-export-value=\"Scenario\"\u003eScenario\u003c\/th\u003e\n\u003cth class=\"fml-scenario-table-column\" scope=\"col\" data-export-value=\"Low Case\"\u003e\n\u003cspan class=\"fml-scenario-column-title\"\u003eLow Case\u003c\/span\u003e\u003cspan class=\"fml-scenario-badge is-soft\"\u003eCash tight\u003c\/span\u003e\n\u003c\/th\u003e\n\u003cth class=\"fml-scenario-table-column\" scope=\"col\" data-export-value=\"Base Case\"\u003e\n\u003cspan class=\"fml-scenario-column-title\"\u003eBase Case\u003c\/span\u003e\u003cspan class=\"fml-scenario-badge is-soft\"\u003eScale path\u003c\/span\u003e\n\u003c\/th\u003e\n\u003cth class=\"fml-scenario-table-column\" scope=\"col\" data-export-value=\"High Case\"\u003e\n\u003cspan class=\"fml-scenario-column-title\"\u003eHigh Case\u003c\/span\u003e\u003cspan class=\"fml-scenario-badge is-warning\"\u003eUpside\u003c\/span\u003e\n\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr data-scenario-row\u003e\n\u003cth class=\"fml-scenario-row-heading\" scope=\"row\" data-export-value=\"Launch model\"\u003e\u003cspan class=\"fml-scenario-row-heading-inner\"\u003e\u003cspan class=\"fml-scenario-row-icon is-launch\" aria-hidden=\"true\"\u003e\u003cimg class=\"fml-scenario-row-icon-img\" src=\"\/cdn\/shop\/files\/scenario-launch-model.svg\" alt=\"Launch model icon\" loading=\"lazy\"\u003e\u003c\/span\u003e\u003cspan\u003e\u003cspan class=\"fml-scenario-row-title\"\u003eLaunch model\u003c\/span\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/th\u003e\n\u003ctd data-export-value=\"This is the launch-year owner-income case, with modest cash left after taxes, debt, reserves, and reinvestment.\"\u003eThis is the launch-year owner-income case, with modest cash left after taxes, debt, reserves, and reinvestment.\u003c\/td\u003e\n\u003ctd data-export-value=\"This is the growth-year owner-income case, with stronger cash left as volume and staffing scale.\"\u003eThis is the growth-year owner-income case, with stronger cash left as volume and staffing scale.\u003c\/td\u003e\n\u003ctd data-export-value=\"This is the mature-year owner-income case, with the strongest modeled cash left if the clinic keeps scaling.\"\u003eThis is the mature-year owner-income case, with the strongest modeled cash left if the clinic keeps scaling.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-scenario-row\u003e\n\u003cth class=\"fml-scenario-row-heading\" scope=\"row\" data-export-value=\"Typical setup\"\u003e\u003cspan class=\"fml-scenario-row-heading-inner\"\u003e\u003cspan class=\"fml-scenario-row-icon is-setup\" aria-hidden=\"true\"\u003e\u003cimg class=\"fml-scenario-row-icon-img\" src=\"\/cdn\/shop\/files\/scenario-typical-setup.svg\" alt=\"Typical setup icon\" loading=\"lazy\"\u003e\u003c\/span\u003e\u003cspan\u003e\u003cspan class=\"fml-scenario-row-title\"\u003eTypical setup\u003c\/span\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/th\u003e\n\u003ctd data-export-value=\"Year 1 models $1.469M revenue and $500k EBITDA, about 34.0% EBITDA margin, with 408 monthly treatments and Month 1 breakeven.\"\u003eYear 1 models $1.469M revenue and $500k EBITDA, about 34.0% EBITDA margin, with 408 monthly treatments and Month 1 breakeven.\u003c\/td\u003e\n\u003ctd data-export-value=\"Year 3 models $4.621M revenue and $3.724M EBITDA, about 80.6% EBITDA margin, with a larger clinical team and steadier utilization.\"\u003eYear 3 models $4.621M revenue and $3.724M EBITDA, about 80.6% EBITDA margin, with a larger clinical team and steadier utilization.\u003c\/td\u003e\n\u003ctd data-export-value=\"Year 5 models $9.272M revenue and $7.668M EBITDA, about 82.7% EBITDA margin, with a full team, fuller capacity, and 13-month payback.\"\u003eYear 5 models $9.272M revenue and $7.668M EBITDA, about 82.7% EBITDA margin, with a full team, fuller capacity, and 13-month payback.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-scenario-row\u003e\n\u003cth class=\"fml-scenario-row-heading\" scope=\"row\" data-export-value=\"Cost drivers\"\u003e\u003cspan class=\"fml-scenario-row-heading-inner\"\u003e\u003cspan class=\"fml-scenario-row-icon is-drivers\" aria-hidden=\"true\"\u003e\u003cimg class=\"fml-scenario-row-icon-img\" src=\"\/cdn\/shop\/files\/scenario-cost-drivers.svg\" alt=\"Cost drivers icon\" loading=\"lazy\"\u003e\u003c\/span\u003e\u003cspan\u003e\u003cspan class=\"fml-scenario-row-title\"\u003eCost drivers\u003c\/span\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/th\u003e\n\u003ctd data-export-value=\"Lower volume; fixed lease and insurance; peptide and lab costs; marketing spend; early staffing mix\"\u003e\u003cul class=\"fml-scenario-list\"\u003e\n\u003cli\u003eLower volume\u003c\/li\u003e\n\u003cli\u003efixed lease and insurance\u003c\/li\u003e\n\u003cli\u003epeptide and lab costs\u003c\/li\u003e\n\u003cli\u003emarketing spend\u003c\/li\u003e\n\u003cli\u003eearly staffing mix\u003c\/li\u003e\n\u003c\/ul\u003e\u003c\/td\u003e\n\u003ctd data-export-value=\"Higher volume; added clinical staff; stronger pricing; ongoing compliance; marketing efficiency\"\u003e\u003cul class=\"fml-scenario-list\"\u003e\n\u003cli\u003eHigher volume\u003c\/li\u003e\n\u003cli\u003eadded clinical staff\u003c\/li\u003e\n\u003cli\u003estronger pricing\u003c\/li\u003e\n\u003cli\u003eongoing compliance\u003c\/li\u003e\n\u003cli\u003emarketing efficiency\u003c\/li\u003e\n\u003c\/ul\u003e\u003c\/td\u003e\n\u003ctd data-export-value=\"Top volume; larger care team; higher prices; lower unit costs; reinvestment pace\"\u003e\u003cul class=\"fml-scenario-list\"\u003e\n\u003cli\u003eTop volume\u003c\/li\u003e\n\u003cli\u003elarger care team\u003c\/li\u003e\n\u003cli\u003ehigher prices\u003c\/li\u003e\n\u003cli\u003elower unit costs\u003c\/li\u003e\n\u003cli\u003ereinvestment pace\u003c\/li\u003e\n\u003c\/ul\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-scenario-row\u003e\n\u003cth class=\"fml-scenario-row-heading\" scope=\"row\" data-export-value=\"Owner income range\"\u003e\u003cspan class=\"fml-scenario-row-heading-inner\"\u003e\u003cspan class=\"fml-scenario-row-icon is-range\" aria-hidden=\"true\"\u003e\u003cimg class=\"fml-scenario-row-icon-img\" src=\"\/cdn\/shop\/files\/scenario-planning-range.svg\" alt=\"Owner income range icon\" loading=\"lazy\"\u003e\u003c\/span\u003e\u003cspan\u003e\u003cspan class=\"fml-scenario-row-title\"\u003eOwner income range\u003c\/span\u003e\u003cspan class=\"fml-scenario-row-subtitle\"\u003eBefore owner reserves\u003c\/span\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/th\u003e\n\u003ctd data-export-value=\"Launch-year owner draw\"\u003e\n\u003cstrong class=\"fml-scenario-range\"\u003eLaunch-year owner draw\u003c\/strong\u003e\u003cspan class=\"fml-scenario-badge is-soft\"\u003eTight cash\u003c\/span\u003e\n\u003c\/td\u003e\n\u003ctd data-export-value=\"Growth-year owner draw\"\u003e\n\u003cstrong class=\"fml-scenario-range\"\u003eGrowth-year owner draw\u003c\/strong\u003e\u003cspan class=\"fml-scenario-badge is-soft\"\u003eGrowth case\u003c\/span\u003e\n\u003c\/td\u003e\n\u003ctd data-export-value=\"Mature-year owner draw\"\u003e\n\u003cstrong class=\"fml-scenario-range\"\u003eMature-year owner draw\u003c\/strong\u003e\u003cspan class=\"fml-scenario-badge is-warning\"\u003eUpside case\u003c\/span\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr data-scenario-row\u003e\n\u003cth class=\"fml-scenario-row-heading\" scope=\"row\" data-export-value=\"Best fit\"\u003e\u003cspan class=\"fml-scenario-row-heading-inner\"\u003e\u003cspan class=\"fml-scenario-row-icon is-fit\" aria-hidden=\"true\"\u003e\u003cimg class=\"fml-scenario-row-icon-img\" src=\"\/cdn\/shop\/files\/scenario-best-fit.svg\" alt=\"Best fit icon\" loading=\"lazy\"\u003e\u003c\/span\u003e\u003cspan\u003e\u003cspan class=\"fml-scenario-row-title\"\u003eBest fit\u003c\/span\u003e\u003c\/span\u003e\u003c\/span\u003e\u003c\/th\u003e\n\u003ctd data-export-value=\"Use this to stress-test take-home pay if growth is slower and the clinic stays lean.\"\u003eUse this to stress-test take-home pay if growth is slower and the clinic stays lean.\u003c\/td\u003e\n\u003ctd data-export-value=\"Use this as the planning case for a clinic that reaches Year 3 scale without a major cash squeeze.\"\u003eUse this as the planning case for a clinic that reaches Year 3 scale without a major cash squeeze.\u003c\/td\u003e\n\u003ctd data-export-value=\"Use this to test upside if utilization, pricing, and staffing all land near plan.\"\u003eUse this to test upside if utilization, pricing, and staffing all land near plan.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\u003c\/div\u003e\n\u003cdiv class=\"fml-scenario-table-note\"\u003e\n\u003cspan class=\"fml-scenario-table-note-icon\" aria-hidden=\"true\"\u003e!\u003c\/span\u003e\u003cp\u003e\u003cstrong\u003ePlanning note:\u003c\/strong\u003e Scenario ranges are researched planning assumptions, not guaranteed earnings, salary promises, tax advice, or distributions.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\u003c\/section\u003e","brand":"FinancialModelsLab","offers":[{"title":"Default Title","offer_id":49304117117171,"sku":"peptide-therapy-owner-makes","price":0.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0522\/6191\/2762\/files\/peptide-therapy-owner-makes.webp?v=1782689057","url":"https:\/\/financialmodelslab.com\/products\/peptide-therapy-owner-makes","provider":"Financial Models Lab","version":"1.0","type":"link"}